Dr. Thomas John of the Olivia Newton-John Cancer Center in Melbourne, Australia presents his favorite breakthroughs in lung cancer from 2014.

For those who wish to access the PDF, it's here: Thomas John, MD Top Four Lung Cancer Highlights 2014

Agree? Disagree? What are you looking forward to in 2015?

Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014

[powerpress]

For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier.

For patients with wild type EGFR, meaning there is no EGFR mutation, drugs like Tarceva (erlotinib) can have a small benefit, but Dr. Joan Schiller wants research to do better. February 2014

[powerpress]

Eighty percent of lung cancer patients have wild type EGFR, meaning there is no EGFR mutation. Dr. Joan Schiller of UT Southwestern Medical Center discusses a new drug in development that may help those patients. February 2014

[powerpress]

Does it make sense to do molecular testing on early stage lung cancer patients? Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute thinks it does in some settings. February 2014

[powerpress]

Will the success seen for stage IV patients receiving targeted therapies translate into cure for stage III patients? Dr. Daniel Morgensztern of the Washington University School of Medicine talks about what research is ongoing to answer that question.

[powerpress]

Leptomeningeal carcinomatosis is cancer that has spread to the coating of the brain and spinal cord. In the past, prognosis has been bad. But now doctors are learning of effective treatments to deal with this issue.

[powerpress]

Drs. Nasser Hanna and Melissa Johnson discuss developments in Immunotherapy since ASCO 2013.

[powerpress]

Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.

[powerpress]